Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 43Triple Negative Breast Neoplasms 19Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 10Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 6Adenocarcinoma 6Cholangiocarcinoma 5Stomach Neoplasms 4Gallbladder Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Adenocarcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Albumin-Bound Paclitaxel × 1 year × Clear all
NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Sun Yat-sen University

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phanes Therapeutics

Phase 1/2 Recruiting
258 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

AHS Cancer Control Alberta

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡